Welcome to CABS 2019 BioPacific Conference
Date: June 22, 2019 @ 8:00 am – @ 7:00 pm
Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Blvd, San Mateo, CA 94402
Download Conference Full Program Here (PDF)
CABS is one of the largest non-profit biopharmaceutical professional organizations in San Francisco Bay Area. As the flagship event of CABS, BioPacific Conference comes to its 21st anniversary in 2019. This year the conference theme is “Pursuing Science for Cure”. The conference is expected to attract more than 600 attendees from >100 biopharmaceutical companies. This year conference features 8 podium talks presented by industry and academic leaders, covering both science and business aspects of biopharma industry. The conference also features 3 panel discussions covering life science investment, contract services in life sciences and next wave of innovative medicine for cancer.
Will you be interested to know?
- 10 Years growth story of BeiGene
- Denali’s new approaches for neurodegenerative disease
- Discovery story behind Talazoparib: 2018 approved therapeutics for breast cancer
- The recent advances in cancer biomarker and precision medicine
- Next wave of cancer therapies and combinations
- 2019 AACR and ASCO update
- The latest foreign investment regulation and policy
Early Bird Price Ended; Please Do Regular Registration
Scroll down to the bottom to register; or use Eventbrite to register.
Registration using a computer is preferred.
Cannot register over iPhone? Read this or use Eventbrite to register
Please contact info@cabsweb.org, if there are any questions.
Featured Podium Talks
Keynote: Biomarkers and translational research in cancer therapy
Ron Mazumder,PhD, VP, Global Head of Oncology Biomarker,Genentech
Dr.Ron Mazumder has more than 20 years experiences in predictive biomarkers and precision medicines. He has served senior positions at J&J and Merck before joining Genentech in 2016. His talk will focus on predictive biomarker and translational research in immuno-oncology.
Talazoparib: From Virtual Drug Discovery to FDA Approval
Leonard Post, PhD, CSO, Vivace Therapeutics
This is a legendary drug discovery story you cannot miss. Talazoparib, a novel PARP inhibitor, was initially discovered in 2007 by a US-based virtual company Lead Therapeutics, with most of its discovery work done in China. Dr. Leonard Post, CSO of Lead Therapeutics, was involved in its discovery. In 2010, BioMarin acquired Talazoparib for $97M and Dr. Post became the CSO of BioMarin. In 2015, Medivation acquired Tapazoparib for $570M and in 2016, Pfizer acquired Medivation. In 2018, Talazoparib was approved for breast cancer. Journey through Talapzoparib for past 12 years, Dr. Leonard Post will share his first-hand experiences from building a virtual company to FDA approval.
CABS 2019 K.Fong Award Speech- The Future of the Biopharma Industry: Innovation Beyond Science
John V. Oyler, Founder, CEO and Chairman, BeiGene
During a dinner in 2010, John Oyler and renowned scientist Dr. Xiaodong Wang decided to “build China’s Genentech” and thus BeiGene was born. Within a decade, John has led BeiGene to be one of China’s most innovative biotech companies. BeiGene is listed in both NASDAQ and HKSE with market capital more than $7B. What are the stories behind BeiGene’s 10 years growth? What is the current status and future of biopharma industry, both in China and in the world? John will share his perspective during CABS 2019 K. Fong award speech. After the speech, Dr. K. Fong and John Oyler, a legendary venture investor and a legendary entrepreneur, will have a face-to-face chat to discuss more on China’s biopharma industry.
New Approaches To Neurodegenerative Disease Drug Discovery and Development
Zachary Sweeney, PhD, Head of Therapeutic Discovery, Denali Therapeutics
Alzheimer’s disease is one of the most difficult diseases in biopharma drug R&D. From 1998 to 2017, there are >100 failed trials for it. Founded by a group of Ex-Genentech veterans in neurosciences and fueled with record-setting Series A funding, Denali believes it can tackle Alzheimer’s disease differently. What are the unique approaches? Before joining Denali, Dr. Zach Sweeney has been senior leaders in Novartis, Genentech and Roche. He will present an overview of selected development programs of Denali.
Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affecting Life Sciences Investment and Licensing
Joseph Benkert, Senior Advisor, National Security Group, Morrison & Foerster
Last summer the Committee on Foreign Investment in the United States (CFIUS) issued new regulations on the review of inbound foreign investments and export control of outbound licensing. What are the impacts of these new regulations on US – China cross-border investment? How to navigate these new changes? Joseph Benkert is a former US Department of Defense Assistant Secretary of Defense for Global Security Affairs under both the Bush and Obama administrations. He has many years experiences handling complex matters before CFIUS. Joseph has presented the latest CFIUS regulations at CABS 2019 Investor Forum in January 2019. He is back to CABS with new updates on CFIUS regulations since January.
Applying Precision Medicine One Patient at a Time
Shivaani Kummar, MD, Professor of Medicine, Stanford University
With the increasing number of anticancer therapeutic choices, it is possible to tailor treatment options based on individual patients. Professor Shivaani Kummar is an internationally renowned expert in cancer therapy clinical trials, especially in early stage trials. She is currently the Director of the Phase I Clinical Research and Translational Oncology Programs at Stanford University, where she has managed ~20 clinical trials in oncology. In this talk, Professor Kummar will focus on using predictive biomarker and genomic drivers to identify the “right” patients and how to design better early clinical trials that can help making key decisions on later stage trials.
New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation |
Jason Liu, PhD, MBA, CEO, WuXi Diagnostics The increasing cancer incidence and mortality accelerate demand for targeted drugs and companion diagnostics and economic pressures to develop maximally efficient treatments in China. With the encouragement from the China government, it’s estimated that by 2021, the market size of companion diagnostics will reach 741 million USD, with CAGR of 28%, far exceeding the global scale as 20.1%. WuXi Diagnostics enables precision medicine through a unique dual-enabling platform for in-vitro diagnostic service and product innovation. Our advanced platform integrates multi-dimensional, multi-omics medical data to generate deep clinical insights, and pioneer innovation by building a novel eco-system for healthcare industry. |
Featured Panel Discussion
Panel Discussion: innovative therapy in oncology, what is next? |
Moderator: Cheni Kwok, PhD, CLP, Managing Partner and Founder, Linear Dreams |
Panelists: |
Wenfeng Xu, PhD, VP, Henlius |
Jean Cui, PhD, CSO, Turning Point Therapeutics |
Mark Nevins, MS, VP of Business Development, Apexigen |
Peiwen Yu, PhD, VP of Discovery Biology, Exelixis |
Tara Arvedson, PhD, Director of Research, Amgen |
Yanyan Zheng, PhD, Principle Scientist, Merck |
|
In this panel discussion, experts from both large biopharma companies such as Amgen and Merck, as well as rising-star oncology startups, will discuss what's next wave of anticancer drugs.
Key Insights from AACR and ASCO 2019
- What was the most exciting data at AACR or ASCO this year?
- What are the emerging hot targets?
Where is the field going in terms of next generation biotherapeutics?
- Antibody formats (ADC, bispecific, multi-specific...)
- New fusion proteins
- Cell therapies (such as CAR T cell, stem cells...)
- Gene therapies (virus-based, modified RNA, anti-sense... )
- Cancer vaccines
What are the future trends for small molecule cancer drugs ?
Conference Agenda (Tentative)
Morning Session |
Keynote: Biomarkers and Translational Research in Cancer Therapy |
Ron Mazumder, PhD, Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech |
New Diagnostics Ecosystem to Accelerate Drug Discovery and Medical Innovation |
Jason Liu, PhD, MBA, CEO, WuXi Diagnostics |
CABS 2019 K. Fong Award in Life Sciences |
Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures |
Award Speech: The Future of the Biopharma Industry: Innovation Beyond Science |
Awardee: John Oyler, Founder, CEO and Chairman of BeiGene |
Designing Therapies to Cure HIV |
Romas Geleziunas, PhD, Executive Director, Gilead Sciences |
Fireside Chat |
Moderator: Alex J. Zhang, PhD, MBA, CEO, Hanhai Silicon Valley |
Jun Xiang, PhD, General Manager, ChemPartner Biologics |
Key Developments: CFIUS, Export Control Reform, and Recent Decisions Affecting Life Sciences Investment and Licensing |
Joseph Benkert, Senior Advisor, Morrison Foerster |
Panel Discussion: IP, legal and investment in Life Sciences |
Moderator, Huijun Zhou, FACMG, Founder and CEO, iDNA |
Panelists: |
Joseph Benkert, Senior Advisor, Morrison Foerster |
Greg Scott, Founder and Chairman, ChinaBio |
Michael Su, MS, JD, Attorney, Intellectual Property Law, Finnegan |
Vivien Wang, MS, Partner, Deloitte |
Lunch Workshop: Humanized Mouse Model Accelerates Biomedicine Research & Drug Development |
Ming Yin, PhD, VP, Beijing VitalStar Biotechnology |
Afternoon Session |
New Approaches To Neurodegenerative Disease Drug Discovery and Development |
Zach Sweeney, PhD, Head of Therapeutic Discovery, Denali Therapeutics |
Panel Discussion: Innovative and Collaborative Contract Services to Accelerate Drug Development |
Moderator, Jiangwen Majeti, PhD, MBA, Genentech |
Panelists, |
Tao He, PhD, Co-Founder and SVP, Joinn Biologics |
Connie Sun, PhD, SVP, Pharmaron |
Mike Chen, CEO, AcroBio |
Applying Precision Medicine One Patient at a Time |
Shivaani Kummar, MD, Professor of Medicine and Director of Phase I Clinical Research Program (Oncology), Stanford University |
Panel Discussion: innovative therapy in oncology, what is next? |
Moderator: Cheni Kwok, PhD, CLP, Managing Partner and Founder, Linear Dreams |
Panelists, |
Wenfeng Xu, PhD, VP, Henlius |
Jean Cui, PhD, CSO, Turning Point Therapeutics |
Mark Nevins, MS, VP of Business Development, Apexigen |
Peiwen Yu, PhD, VP of Discovery Biology, Exelixis |
Tara Arvedson, PhD, Director of Research, Amgen |
Yanyan Zheng, PhD, Principle Scientist, Merck |
Talazoparib: From Virtual Drug Discovery to FDA Approval |
Leonard Post, PhD, CSO, Vivace Therapeutics |
More Details About Our Speakers
Program/Agenda (PDF)
Podium Speakers Bio (PDF)
Discussion Panelists Bio (PDF)
Early Bird Price Ended; Please Do Regular Registration
Scroll down to the bottom to register; or use Eventbrite to register.
Registration using a computer is preferred.
Cannot register over iPhone? Read this or use Eventbrite to register
Please contact info@cabsweb.org, if there are any questions.
Refreshments, lunch and evening reception/happy hour are included.
CABS Member | Early Bird Registration (by 6/7/2019) | Regular Registration (6/8/2019- 06/21/2019) |
General | $60 | $100 |
Academic | $40 Please use your institution email (.edu) |
$80 Please use your institution email (.edu) |
Non-Member* | Early Bird Registration (by 6/7/2019) | Regular Registration (6/8/20189-06/21/2019) |
General | $90 | $130 |
Academic | $70 Please use your institution email (.edu) |
$110 Please use your institution email (.edu) |
* Join CABS today ($30 for one year membership) to save on registration fee: http://www.cabsweb.org/members/
Thanks to our Sponsors!
As of May 27, 2019, all exhibition tables for 2019 BioPacific Conference have been reserved by sponsors. If you have not received invoices from CABS, please do not pay online directly. You are very welcome to contact fundraising@cabsweb.org if you still wish to sponsor CABS without exhibition table. Thank you very much!
Please use your own edu email address to register.
.edu email address is required
Please use your own edu email address to register.
.edu email address is required
Special code required. This is for the following types: Speakers and Panelists, VIP Partners, VIP Guests, Event Organizers and Volunteers.
.